更新于：2024-11-21

Ethinyl Estradiol/Norethindrone Acetate/Ferrous Fumarate

炔雌醇/醋炔诺酮/富马酸铁

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名

ETHINYL ESTRADIOL/FERROUS FUMARATE/NORETHINDRONE、ETHINYL ESTRADIOL/FERROUS FUMARATE/NORETHINDRONE ACETATE、NORETHINDRONE ACETATE/ETHINYL ESTRADIOL/ETHINYL ESTRADIOL/FERROUS FUMARATE

+ [5]

靶点

ER x PR

作用机制

ERs激动剂(雌激素受体家族激动剂)、PR激动剂(孕激素受体激动剂)

治疗领域

其他疾病

在研适应症

避孕

非在研适应症-

原研机构

Pfizer Inc.

在研机构

Viatris Holdings LLC

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1978-02-21),

避孕

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C22H28O3

InChIKeyIMONTRJLAWHYGT-ZCPXKWAGSA-N

CAS号51-98-9

查看全部结构式(3)

关联

项与炔雌醇/醋炔诺酮/富马酸铁相关的临床试验

NCT06460948 / Not yet recruiting早期临床1期IIT

Characterizing Oxytocin Response to Oral Estrogen Administration in Adults With Arginine Vasopressin Deficiency

This is an open-label, pilot study, to characterize oxytocin response to a single dose of oral Estrogen-progestin in patients with arginine-vasopressin deficiency compared to healthy controls. The association between oxytocin levels and measures of psychopathology (i.e., anxiety and depression) and quality of life across groups will be examined. We hypothesize that:
1. Salivary and blood oxytocin response to Estrogen-progestin will be lower in arginine-vasopressin deficiency compared to healthy control.
2. Lower salivary and blood oxytocin levels will be associated with more severe symptoms of anxiety, depression, and social emotional difficulties as well as lower quality of life.

开始日期2024-06-01

申办/合作机构

The General Hospital Corp.

NCT01318005 / Unknown statusN/AIIT

The Effects of Dose and Formulation of Oral Contraceptives (OCs) on Breast-Cell Proliferation: Can the Chemopreventive Effects of OCs on Endometrial and Ovarian Cancer be Extended to Breast Cancer?

The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of estrogen (a hormone in the birth control pill) may have lower breast cell growth than women who use birth control pills with a higher amount of estrogen; this research will examine that in detail. This research will also test whether the results found in HS-07-00269 can be confirmed.

开始日期2011-01-01

申办/合作机构

University of Southern California

NCT00391807 / Completed临床3期

Open-Label Study of the Safety and Efficacy of a Low Dose Oral Contraceptive Containing Norethindrone Acetate and Ethinyl Estradiol

This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.

开始日期2006-11-01

申办/合作机构

Warner Chilcott Ltd.

100 项与炔雌醇/醋炔诺酮/富马酸铁相关的临床结果

登录后查看更多信息

100 项与炔雌醇/醋炔诺酮/富马酸铁相关的转化医学

登录后查看更多信息

100 项与炔雌醇/醋炔诺酮/富马酸铁相关的专利（医药）

登录后查看更多信息

100 项与炔雌醇/醋炔诺酮/富马酸铁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G03CA	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
避孕	美国	Viatris Holdings LLC	1978-02-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00932321 (CTgov)	临床3期	避孕	938	Norethindrone Acetate/Ethinyl Estradiol 24 Days (24 Day NA/EE)	簾網糧遞鹹窪築艱鹹選(顧觸顧構遞糧蓋醖窪淵) = 鹽製繭網夢鬱構襯蓋製鑰製鹽鏇壓遞鏇憲網夢 (壓餘壓構遞積壓製鹹鑰, 壓餘淵構觸鹹艱憲簾淵 ~ 糧鏇鏇廠廠齋鹹餘餘衊) 更多	-	2011-03-22
				Norethindrone Acetate /Ethinyl Estradiol 21 Days (21 Day NA/EE)	簾網糧遞鹹窪築艱鹹選(顧觸顧構遞糧蓋醖窪淵) = 醖選觸夢齋衊觸鹹繭顧鑰製鹽鏇壓遞鏇憲網夢 (壓餘壓構遞積壓製鹹鑰, 襯鏇壓積構簾鑰繭觸簾 ~ 餘廠範製膚鹽鬱艱餘築) 更多